FDA Approves Foundayo (Orforglipron) — First Daily Oral GLP-1 Pill for Weight Loss
Eli Lilly's Foundayo becomes the first once-daily oral GLP-1 receptor agonist approved by the FDA, eliminating the need for injections in obesity treatment.
Source: Medical News Today
Stanford Researchers Discover BRP Peptide — A Potential Side-Effect-Free Alternative to Ozempic
Stanford scientists have identified a novel brain-targeted peptide called BRP that suppresses appetite as effectively as GLP-1 drugs but without nausea or muscle loss in animal models.
Source: ScienceDaily
Medicare to Launch GLP-1 Coverage Demonstration Program in July 2026
CMS announces a new payment demonstration that will provide Medicare beneficiaries with access to GLP-1 medications for obesity, bridging to the full BALANCE Model in 2027.
Source: CMS.gov
GLP-1 Drugs Show Promise for Addiction Treatment in Emerging Research
Harvard researchers outline expanding clinical applications for GLP-1 peptides beyond weight loss, including early evidence of reduced cravings in substance use disorders.
Source: Harvard Gazette
Mitochondrial Peptides Emerge as Major Research Category in 2026
MOTS-C and humanin are moving from niche curiosities to recognized research targets, with new studies exploring their roles in aging, metabolism, and exercise mimicry.
Source: Alpha Peptides
Novartis Wins Expanded FDA Approval for Peptide-Based Prostate Cancer Therapy Pluvicto
Pluvicto (lutetium-177 vipivotide tetraxetan) receives expanded approval for use before chemotherapy in metastatic prostate cancer, showing a 28% reduction in disease progression risk.
Source: Peptide Protocol Wiki
Global Peptide Synthesis Market Hits $1.9 Billion as Demand Surges
A new industry report shows the global research peptide market has reached $1.9 billion in 2026, driven by therapeutic demand and projected to hit $2.59 billion by 2031.
Source: GlobeNewsWire
Genetic Study Reveals 10% of Population May Be Resistant to GLP-1 Diabetes Drugs
Stanford researchers have identified genetic variants carried by roughly one in ten people that significantly reduce the effectiveness of GLP-1 receptor agonists for blood sugar control.
Source: Stanford Medicine
Eli Lilly's Retatrutide Delivers Record 71-Pound Average Weight Loss in Phase 3 Trial
The triple-agonist peptide retatrutide achieved unprecedented weight loss in the TRIUMPH-4 trial while also providing substantial relief from osteoarthritis knee pain.
Source: Eli Lilly Investor Relations
14 Peptides Including BPC-157 and TB-500 Reclassified Back to Legal Compounding Status
HHS Secretary Kennedy announces that 14 previously restricted peptides will return to Category 1, restoring access through compounding pharmacies with a prescription.
Source: Peptibase
Daily Briefing
Get the latest peptide research delivered to your inbox every morning.
The Peptide Wizard
High-quality research peptides for lab use. Third-party tested with certificate of analysis available on every product.
Visit The Peptide WizardSponsored content. ThePBrief receives compensation. For research purposes only.